Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1522893 | 0.95 | MAPK14 (0.65) | MAPK14MCHR1CYP2D6HRH1HRH3 | |
| SCHEMBL26017766 | 0.83 | MAPK14 (0.64) | MAPK14MCHR1 | |
| SCHEMBL6470884 | 0.83 | MAPK14 (0.54) | MAPK14MCHR1KCNH2 | |
| SCHEMBL2177074 | 0.81 | MAPK14 (1.00) | MAPK14MCHR1 | |
| SCHEMBL4484736 | 0.80 | MAPK14 (0.76) | MAPK14MCHR1KCNH2 | |
| SCHEMBL27602601 | 0.80 | MCHR1 (0.54) | MAPK14MCHR1KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4470437 | 0.78 | MAPK14 (0.48) | MAPK14MCHR1KCNH2 | |
| SCHEMBL18324516 | 0.78 | MAPK14 (0.72) | MAPK14MCHR1KCNH2 | |
| SCHEMBL4045555 | 0.78 | MAPK14 (0.72) | MAPK14MCHR1 | |
| SCHEMBL4488171 | 0.77 | HTR6 (0.50) | MAPK14MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | ADDEX PHARMACEUTICALS S.A. (CH) | 2021-07-27 | — | — | US | disclosed |
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | ADDEX PHARMACEUTICALS S.A. (CH) | 2021-07-27 | — | — | US | disclosed |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2020-02-06 | — | — | US | disclosed |
| US-20150336930-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336930-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | JANSSEN PHARMACEUTICALS INC (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2203439-B1 | 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-Ý1, 4'¨BIPYRIDINYL-2'-ONES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010025890-A1 | 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033704-A1 | 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071729-B2 | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones | GRM2, GRM1, GRIN2C | MAPK14 3169/4885MCHR1 405/4885CYP2D6 397/4885 |
| US-20220000856-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | MAPK14 3195/4885MCHR1 363/4885CYP2D6 388/4885 |
| US-20200038391-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | MAPK14 3195/4885MCHR1 363/4885CYP2D6 388/4885 |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | MAPK14 2957/4885MCHR1 564/4885CYP2D6 597/4885 |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | MAPK14 177/4885MCHR1 4588/4885CYP2D6 1692/4885 |
| US-20100240688-A1 | 1,3-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1 H-1,4 BIPYRIDINYL-2-ONES | GRM2, GRM1, GRM3 | MAPK14 3288/4885MCHR1 349/4885CYP2D6 541/4885 |
| US-20150336930-A1 | 1',3'-Disubstituted-4-Phenyl-3,4,5,6-Tetrahydro-2H,1'H-[1,4']Bipyridinyl-2'-Ones | GRM2, GRM1, GRIN2C | MAPK14 3195/4885MCHR1 363/4885CYP2D6 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.